Display options
Cite
Hajizadeh N, Assadi F. Resistant hypertension: current status, future challenges. Int J Prev Med. 2014;5:S21-4
Hajizadeh, N., & Assadi, F. (2014). Resistant hypertension: current status, future challenges. International journal of preventive medicine, 5S21-4.
Hajizadeh, Niloofar, and Assadi, Farahnak. "Resistant hypertension: current status, future challenges." International journal of preventive medicine vol. 5 (2014): S21-4.
Hajizadeh N, Assadi F. Resistant hypertension: current status, future challenges. Int J Prev Med. 2014 Mar;5:S21-4. PMID: 24791187; PMCID: PMC3990922.
Copy Download .nbib Format: NLM
Share it on

Int J Prev Med. 2014 Mar;5:S21-4.

Resistant hypertension: current status, future challenges.

International journal of preventive medicine

Niloofar Hajizadeh, Farahnak Assadi

Affiliations

  1. Department of Pediatrics, Division of Nephrology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  2. Emeritus Professor of Pediatrics, Section of Nephrology, Rush University Medical Center, Chicago, Illinois USA, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

PMID: 24791187 PMCID: PMC3990922

Abstract

Resistant hypertension in adolescents is increasing in frequency and is increasingly recognized as having significant short- and long-term health consequences. It may be seen in up to 30% of all hypertensive patients cared for. Adolescents with resistant hypertension are at higher cardiovascular (CV) risk due to a long history of severe hypertension complicated by other CV risk factors such as obesity. Common causes of resistant hypertension include primary aldosteronism, sleep apnea, diabetes and chronic kidney disease. Careful blood pressure (BP) measurement and thorough evaluation of patients with sustained BP elevation should make a possible early diagnosis of resistant hypertension. Successful treatment requires identification and reversal of life-style factors contributing to treatment resistant and diagnosis and appropriate treatment of causes of hypertension. Improved pharmacologic therapies may offer the potential for preventing or at least ameliorating early CV disease. This review highlights these and other important issues in the evaluation and management of adolescents with resistant hypertension and provides practical guidance to the practitioners involved in caring for such patients.

Keywords: Cardiovascular disease; children and adolescents; prevention; resistant hypertension

References

  1. J Am Soc Nephrol. 2012 Jul;23(7):1250-7 - PubMed
  2. Curr Cardiol Rep. 2009 Nov;11(6):407-13 - PubMed
  3. Best Pract Res Clin Endocrinol Metab. 2010 Dec;24(6):923-32 - PubMed
  4. Circulation. 2008 Jun 24;117(25):e510-26 - PubMed
  5. J Am Coll Cardiol. 2011 Sep 6;58(11):1152-61 - PubMed
  6. Hypertension. 2009 Sep;54(3):475-81 - PubMed
  7. Am J Hypertens. 2003 Nov;16(11 Pt 1):925-30 - PubMed
  8. Tech Vasc Interv Radiol. 2010 Jun;13(2):110-25 - PubMed
  9. Lancet. 2009 Apr 11;373(9671):1275-81 - PubMed
  10. J Nephrol. 2013 Jan-Feb;26(1):41-7 - PubMed
  11. Arch Intern Med. 2008 Jun 9;168(11):1159-64 - PubMed
  12. Hypertension. 2011 May;57(5):898-902 - PubMed
  13. Lancet. 2003 Jan 11;361(9352):117-24 - PubMed
  14. Eur Heart J. 2010 Sep;31(18):2205-8 - PubMed
  15. Pediatr Cardiol. 2012 Oct;33(7):1013-20 - PubMed
  16. Circulation. 2012 Dec 18;126(25):2976-82 - PubMed
  17. Hypertension. 2011 Jun;57(6):1069-75 - PubMed
  18. Am J Hypertens. 2002 Apr;15(4 Pt 1):333-9 - PubMed
  19. J Hypertens. 2001 Nov;19(11):2063-70 - PubMed
  20. Curr Hypertens Rep. 2007 Nov;9(5):353-9 - PubMed
  21. Curr Hypertens Rep. 2008 Dec;10(6):496-503 - PubMed
  22. Am J Hypertens. 2005 May;18(5 Pt 1):619-26 - PubMed
  23. Minerva Cardioangiol. 2009 Dec;57(6):787-812 - PubMed

Publication Types